Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and ...

Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and ...

RESEARCH TRIANGLE PARK, N.C., May 1 /PRNewswire-FirstCall/ -- Late yesterday the U.S. Food and Drug Administration approved Advair Diskus(R) 250/50 (fluticasone ...

Advair 250/50 was prescribed for me over 10 years ago, and I’ve been taking it regularly each morning, thoroughly rinsing each time to prevent thrush. About five years ago, I developed an ...

Co annonces the FDA has issued a not approvable letter for the supplemental drug application for the 500/50 strength of Advair Diskus in the ... the currently approved 250/50 strength in order ...

TORONTO, RESEARCH PARK, N.C. According to new research, GlaxoSmithKline’s asthma drug Advair Diskus 250/50 demonstrated a 30 percent reduction in exacerbations in patients with chronic ...

250/50 mcg and 500/50 mcg) to the U.S. Food and Drug Administration (FDA), by its strategic alliance partner, Respirent Pharmaceuticals Co. Ltd. The product is the generic equivalent of ADVAIR ...

The FDA also expanded the use of Advair Diskus 250/50 to a broader patient population which includes not only patients with COPD associated with chronic bronchitis, but also emphysema or both ...

RESEARCH TRIANGLE PARK, N.C., April 30 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration today approved Advair Diskus(R) 250/50 (fluticasone propionate ...

RESEARCH TRIANGLE PARK, N.C., May 1 Lateyesterday the U.S. Food and Drug Administration approved Advair Diskus(R)250/50 (fluticasone propionate 250 mcg and salmeterol 50 mcg inhalationpowder ...